Literature DB >> 12142733

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

Marco Niedergethmann1, Ralf Hildenbrand, Birgit Wostbrock, Mark Hartel, Jörg W Sturm, Axel Richter, Stefan Post.   

Abstract

INTRODUCTION AND AIMS: Only curative resection for pancreatic adenocarcinoma is related to a favorable prognosis, but the overall survival after surgery still remains poor, and early recurrence is frequently observed. Because recurrence is the limiting factor and the main cause of death after curative resection, the identification of markers that predict early postoperative recurrence is of paramount importance. Angiogenesis is essential for tumor growth and metastases; therefore, we set out to clarify whether vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) correlate with early recurrence and poor prognosis after curative resection. A second goal was to characterize the VEGF-producing cells and the subcellular distribution.
METHODOLOGY: Seventy patients with ductal adenocarcinoma of the pancreas were studied after curative resection with a follow-up of at least 2 years. The MVD quantification was performed immunohistochemically with use of a monoclonal antibody to CD34. The VEGF expression was studied with use of polyclonal antibody. To detect the intracellular localization of specific VEGF mRNA sequences, nonisotopic in situ hybridization was performed. The correlations among VEGF expression and MVD, clinicopathologic parameters, and clinical outcome were then statistically analyzed.
RESULTS: The VEGF immunoreactivity was 88.6%, and positive mRNA signals were obtained in the cytoplasm of carcinoma and endothelial cells in 81.4%. Furthermore, we observed tumor-associated macrophages close to infiltrating carcinoma cells. All endothelial cells showed positive immunoreactivity to the anti-CD34 antibody, and a median distribution of 85 vessels/x200 field was observed. A significant correlation (p < 0.05) was found between the MVD and the International Union Against Cancer (UICC) stage. Statistical analysis showed a significant correlation between VEGF expression and the height of MVD (p < 0.05). Kaplan-Meier analyses revealed that VEGF expression and MVD had a statistically significant correlation with survival after curative resection (p < 0.05). Furthermore, multivariate analysis indicated that VEGF expression is an independent prognostic marker for cancer recurrence within 8 months after curative surgery (p = 0.003).
CONCLUSION: In pancreatic adenocarcinoma, the VEGF expression and the height of MVD are closely correlated, and both-rather than UICC stage and TNM classification (tumor size and nodal involvement)-are markers of prognostic relevance after curative resection. Furthermore, VEGF is a predictor of early recurrence after curative resection. The current study indicates that VEGF may promote the distribution of metastases, leading to early cancer recurrence and poor outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142733     DOI: 10.1097/00006676-200208000-00002

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  65 in total

1.  Xenon-inhalation computed tomography for noninvasive quantitative measurement of tissue blood flow in pancreatic tumor.

Authors:  Masaru Kubota; Takamichi Murakami; Hiroaki Nagano; Hidetoshi Eguchi; Shigeru Marubashi; Shogo Kobayashi; Hiroshi Wada; Masahiro Tanemura; Keizo Dono; Shoji Nakamori; Masato Sakon; Morito Monden; Masaki Mori; Yuichiro Doki
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 3.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

4.  CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.

Authors:  Xiaolin Wan; Na Shen; Arnulfo Mendoza; Chand Khanna; Lee J Helman
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 5.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 6.  Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis.

Authors:  Yoko Matsuda; Masahito Hagio; Toshiyuki Ishiwata
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Prognostic value of tumor-related molecular expression in gastric carcinoma.

Authors:  Zhong-Sheng Zhao; Yuan-Yu Wang; Zai-Yuan Ye; Hou-Quan Tao
Journal:  Pathol Oncol Res       Date:  2009-03-18       Impact factor: 3.201

9.  Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.

Authors:  Ali Arshad; Wen Y Chung; William Steward; Matthew S Metcalfe; Ashley R Dennison
Journal:  HPB (Oxford)       Date:  2012-11-22       Impact factor: 3.647

10.  Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas.

Authors:  Yu Tian; Li-Li Zhu; Ren-Xuan Guo; Chui-Feng Fan
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.